95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Cell Death
Sec. Cellular Stress and Survival: Crosslinks, Intersections, and Pathways
Volume 4 - 2025 | doi: 10.3389/fceld.2025.1583221
This article is part of the Research Topic Posttranslational Modifications in Life and Death Decisions View all articles
The Good, the Bad, and the Modified: CYLD's Post-Translational Tale
Provisionally accepted- Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
The deubiquitinating enzyme CYLD hydrolyzes Lys63- and Met1-linked ubiquitin chains, playing a crucial role in regulating various cellular processes such as immune cell development, innate and adaptive immunity, spermatogenesis, ciliogenesis, and cell survival. CYLD also functions as a tumor suppressor and is mutated in familial cylindromatosis. This pleiotropic function implies tight regulatory mechanisms. In this review, we summarize the current knowledge on CYLD’s molecular characteristics, subcellular location, and binding partners, with a focus on its involvement in life-and-death decisions. In addition, we discuss how post-translational modifications, including phosphorylation, ubiquitination, and proteolysis, shape the CYLD’s function, unveiling the potential for therapeutic intervention. Finally, we highlight the remaining challenges that need to be overcome to deepen our understanding of this crucial enzyme.
Keywords: CYLD, DUB, Cell Death, post-translational modifications, Phosphorylation, Ubiquitin, Proteolysis
Received: 25 Feb 2025; Accepted: 27 Mar 2025.
Copyright: © 2025 Macé, Bidere and Douanne. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Tiphaine Douanne, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.